COMPOSITIONS AND METHODS RELATED TO RAD51 INACTIVATION IN THE TREATMENT OF NEOPLASTIC DISEASES, AND ESPECIALLY CML
摘要
<p>Chronic myelogenous leukemia (CML), and in particular imatinib resistant CML is treated using compositions and methods in which a Rad51-inhibitor and a kinase inhibitor are administered. Most preferably, the Rad51 inhibitor comprises an indolyl isoquinoline structure and the kinase inhibitor is a BCR-ABL inhibitor.</p>
申请公布号
WO2007120726(A2)
申请公布日期
2007.10.25
申请号
WO2007US08969
申请日期
2007.04.10
申请人
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA;LEE, WEN-HWA;CHEN, PHANG-LANG;ZHOU, LONGEN;ZHU, JIEWEN
